GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the Phase 2 portion of its ongoing Phase 1/2 study evaluating its novel E-selectin antagonist, GMI-1271, combined with chemotherapy. Earlier this month, the company announced it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GMI-1271 for treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML. In addition, GlycoMimetics recently announced that the first patient with relapsed or refractory AML has been dosed in the other arm of the Phase 2 portion of this study.

Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has been awarded a grant from the National Institute on Drug Abuse (“NIDA”) at the National Institutes of Health. The grant of approximately $1.0 million provides Cerecor with additional resources for the ongoing Phase 2 clinical trial for CERC-501, “A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.”

Digital health technology leader WellDoc® has expanded its leadership team with two new C-level executives and a key executive director. Healthcare finance veteran Jeff Lehrfeld has joined the company from Magellan Health as Chief Financial Officer (CFO), and senior marketing executive Tara Charvat, MBA, is the company’s new Chief Marketing Officer (CMO), joining from Valeritas. In addition, Christina Hedge is the new Executive Director, Market Access, reporting to Nick Harsh, Vice President, Market Access, who came to WellDoc this Spring.

More women are studying science, technology, engineering and math at UC San Diego than at any other major college in the country, a recent analysis of enrollment has found.

The study conducted by BestColleges.com found that one in three women at UC San Diego graduate with a STEM degree, about three times the national average.

Wexford Science & Technology LLC will soon again be under new ownership.

Chicago-based Ventas Inc. has agreed to pay $1.5 billion in cash to acquire substantially all of the assets of the Baltimore real estate investment and development firm from affiliates of Blackstone Real Estate Partners VIII L.P. Ventas will also assume $33 million of liabilities. The deal is expected to close in the fourth quarter.

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets, supporting the exploding supernova known as immuno-oncology.

Businesses that set out to change the world might want to start in D.C.

That’s according to a new study from D.C.-based S&R Foundation’s Halcyon Incubator, which calls Washington the best U.S. city for “social entrepreneurs” — startup founders that attempt to solve social problems with scalable businesses, like the Georgetown grads tackling food-waste with their juicing company, Misfit Juicery.

The American Cancer Society has handed out $3.84 million in grants to Maryland cancer researchers at the University of Maryland, Johns Hopkins University and the National Cancer Institute for a range of investigations.

NEA Parnter Sara Nayeem will speak on a panel at the Orphan Drugs and Rare Diseases Conference on Tuesday, June 28, 2016 at Westin Copely Place Boston in Boston, MA. Dr. Nayeem will participate in the panel entitled, Funding Early Opportunities in Orphan and Rare Disease Space: What To Look Out For?

D.C. venture capital powerhouse Updata Partners will announce Thursday that it has raised $280.6 million in new funding.

Updata, whose portfolio includes Mashable and VideoBlocks, surpassed its goal for the Updata Partners V LP fund by about $5 million. As of April, it had reported raising $160 million to the Securities and Exchange Commission.

Vice President Joe Biden, who has personal experience of the heartbreak that cancer causes, has taken on humanity’s mortal enemy and aims to end the disease “as we know it.”

The White House’s Cancer Moonshot 2020 is about much more than clinical research. Data, IT and patient engagement are major components.

Vice President Joe Biden on Wednesday is hosting the first National Cancer Moonshot Summit on the campus of Howard University in Washington, and lots of news is being made.

Could lab-grown bones replace tissue grafts and multiple painful surgeries? Nina Tandon is the CEO and co-founder of EpiBone, a Brooklyn-based biotech company that was chosen as one of the World Economic Forum's 2015 Technology Pioneers. Tandon is also a World Economic Forum Young Scientist who will be speaking at the Annual Meeting of the New Champions in Tianjin, China, from June 26 to 28.

The Biotechnology Innovation Organization today released the following statement in response to Democratic Presidential Candidate Hillary Clinton’s Initiative on Technology & Innovation:

“As one of America’s most innovative industries, biotechnology is tackling head-on the unrelenting scientific challenges inherent in the discovery, development and delivery of new, high-value healthcare, agricultural, industrial and environmental products.

The Cleveland Health-Tech Corridor said it has teamed up with JumpStart Inc. to launch a $2 million investment and attraction fund to provide financial capital for businesses willing to move to the corridor district that links downtown and University Circle.

Last week, Great Britain voted to leave the European Union of 28 member states, or “Brexit.” Since the result was announced sterling has fallen to a 31-year low, there has been a record daily drop in global equity markets and political turmoil has broken out as the UK Prime Minister has said he will step down and the majority of the leadership team of the official opposition party has resigned.